<DOC>
	<DOCNO>NCT00193492</DOCNO>
	<brief_summary>The purpose study assess feasibility , efficacy safety add bevacizumab rituximab compare rituximab alone patient previously treat follicular non-hodgkin 's lymphoma ( NHL ) whose disease progress follow least one previous chemotherapy regimen 2 previous chemotherapy regimen .</brief_summary>
	<brief_title>A Study Rituximab Bevacizumab Patients With Follicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Upon determination eligibility , patient randomly assign one two treatment arm : - Rituximab - Rituximab + bevacizumab For every 2 patient randomize , 1 receive treatment number 1 ( rituximab ) , 1 patient receive treatment number 2 ( rituximab + bevacizumab ) . This blind study , patient doctor know treatment assign .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>To include study , must meet following criterion : Follicular NHL , grade 1 2 confirm biopsy sample 18 year age old Evidence disease progression time study entry Must least one previous chemotherapy regimen two previous chemotherapy regimen . Patients receive previous rituximab eligible long progression occur six month follow completion previous rituximab therapy . Measurable evaluable disease Able perform activity daily live without considerable assistance Adequate bone marrow , kidney , liver function Signed informed consent obtain prior initiation studyspecific procedure treatment . You participate study follow apply : Treatment two previous chemotherapy regimens Prior treatment bevacizumab similar agent Progressive NHL le 6 month receive previous rituximab More 1 prior treatment investigational agent within 4 week prior enter study Spread NHL brain nervous system History uncontrolled significant disease medical condition may put high risk treatment complication agent Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may . You decide wish participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Rituximab</keyword>
</DOC>